Tuesday, December 08, 2020 12:52:39 PM
Just assume for a moment that researchers are opining, from the compassionate and expanded use arm knowledge, that PFS and OS are “in the bag.” How could you even make a run at rGBM, when it was not an initial goal of the phase iii? This question made me previously doubt folks in the rGBM camp after they saw the new endpoint arrangement.
However, what better order of endpoints, if Original PFS and OS are in the bag, then to wrap in rGBM with the same logic?
In other words, for rGBM, assuming all endpoints below are successful:
Given:
Primary endpoint nGBM = DCVAx against historical SOC nGBM, which was is/was predicted by secondary endpoints ii cPFS and iii (PFS) and v. (tumor response) Annndddd, those secondary endpoints just mentioned also predicted secondary endpoint iv (original OS).
Therefore,
Secondary endpoint i rGBM = DCVAx Against historical SOC rGBM, which is also predicted by secondary endpoints ii cPFS and iii (PFS) and v. (tumor response).
Then add the equivalent of a phase iv. confirmation trial (initial enrollment starting a year ago), in the guise of a combo trial, utilizing DCvAx-l SOC arm w/poly-iclc (something they’ve proven safe in other trials), and compare it to the treatment plus adjuvant (aka: given before and after tumor removal) Keytruda arm.
Very clever and efficient despite the current long phase iii nGBM trial.
Finally, those same predictive type of endpoints in the granddaddy phase iii trial can then be used to make shorter surrogate trials for other cancer indications (We’ve discussed this before). That intellectual property predictive property gained from the granddaddy phase iii trial placing a very effective barrier to entry against competition.
WEAR A MASK.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM